Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 5.3% Higher - Should You Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares rose 5.3% on Friday . The company traded as high as $7.68 and last traded at $7.59. Approximately 5,773,886 shares changed hands during trading, a decline of 46% from the average daily volume of 10,779,051 shares. The stock had previously closed at $7.21.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $9.25.

Recursion Pharmaceuticals Stock Up 8.2 %

The firm has a market cap of $3.05 billion, a price-to-earnings ratio of -5.10 and a beta of 0.85. The stock's 50 day moving average is $6.87 and its 200 day moving average is $7.08. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm's revenue for the quarter was up 147.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.43) earnings per share. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $6.31, for a total value of $37,860.00. Following the transaction, the chief operating officer now owns 521,138 shares in the company, valued at approximately $3,288,380.78. The trade was a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total value of $76,351.49. Following the sale, the director now owns 7,089,007 shares of the company's stock, valued at $47,283,676.69. This trade represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 70,341 shares of company stock valued at $488,290. 15.75% of the stock is owned by insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC boosted its position in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after purchasing an additional 4,948 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Recursion Pharmaceuticals by 6.1% in the third quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company's stock worth $7,751,000 after buying an additional 67,464 shares during the period. Franklin Resources Inc. increased its position in shares of Recursion Pharmaceuticals by 58.9% in the third quarter. Franklin Resources Inc. now owns 18,963 shares of the company's stock worth $127,000 after acquiring an additional 7,027 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals during the third quarter valued at approximately $89,000. Finally, Geode Capital Management LLC raised its holdings in shares of Recursion Pharmaceuticals by 13.7% during the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock valued at $35,803,000 after acquiring an additional 656,003 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.